biostudies-literatureMansukhani MPNIA NIH HHS119-128https://www.ebi.ac.uk/biostudies/studies/S-EPMC6329537biostudies-literatureUnknown15(1)<h4>Study objectives</h4>Adaptive servoventilation (ASV) is the suggested treatment for many forms of central sleep apnea (CSA). We aimed to evaluate the impact of treating CSA with ASV on health care utilization.<h4>Methods</h4>In this population-based study using the Rochester Epidemiology Project database, we identified patients over a 9-year period who were diagnosed with CSA (n = 1,237), commenced ASV therapy, and had ? 1 month of clinical data before and after ASV initiation. The rates of hospitalizations, emergency department visits (EDV), outpatient visits (OPV) and medications prescribed per year (mean ± standard deviation) in the 2 years pre-ASV and post-ASV initiation were compared.<h4>Results</h4>We found 309 patients (68.0 ± 14.6 years, 80.3% male, apnea-hypopnea index 41.6 ± 26.5 events/h, 78% with cardiovascular comorbidities, 34% with heart failure) who met inclusion criteria; 65% used ASV ? 4 h/night on ? 70% nights in their first month. The overall 2-year mortality rate was 9.4% and CSA secondary to cardiac cause was a significant risk factor for mortality (hazard ratio 1.81, 95% CI 1.09-3.01, <i>P</i> = .02). Comparing pre-ASV and post-ASV initiation, there was no change in the rate of hospitalization (0.72 ± 1.63 versus 0.79 ± 1.44, <i>P</i> = .46), EDV (1.19 ± 2.18 versus 1.26 ± 2.08, <i>P</i> = .54), OPV (31.59 ± 112.42 versus 13.60 ± 17.36, <i>P</i> = .22), or number of prescribed medications (6.68 ± 2.0 versus 5.31 ± 5.86, <i>P</i> = .06). No differences in these outcomes emerged after accounting for adherence to ASV, CSA subtype and comorbidities via multiple regression analysis (all <i>P</i> > .05).<h4>Conclusions</h4>Our cohort of patients with CSA was quite ill and the use of ASV was not associated with a change in health care utilization.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep MedicineEffects of Adaptive Servoventilation Therapy for Central Sleep Apnea on Health Care Utilization and Mortality: A Population-Based Study.PMC6329537R01 AG034676Gay PCKolla BPMorgenthaler TINaessens JMMansukhani MPfalseEffects of Adaptive Servoventilation Therapy for Central Sleep Apnea on Health Care Utilization and Mortality: A Population-Based Study.<h4>Study objectives</h4>Adaptive servoventilation (ASV) is the suggested treatment for many forms of central sleep apnea (CSA). We aimed to evaluate the impact of treating CSA with ASV on health care utilization.<h4>Methods</h4>In this population-based study using the Rochester Epidemiology Project database, we identified patients over a 9-year period who were diagnosed with CSA (n = 1,237), commenced ASV therapy, and had ? 1 month of clinical data before and after ASV initiation. The rates of hospitalizations, emergency department visits (EDV), outpatient visits (OPV) and medications prescribed per year (mean ± standard deviation) in the 2 years pre-ASV and post-ASV initiation were compared.<h4>Results</h4>We found 309 patients (68.0 ± 14.6 years, 80.3% male, apnea-hypopnea index 41.6 ± 26.5 events/h, 78% with cardiovascular comorbidities, 34% with heart failure) who met inclusion criteria; 65% used ASV ? 4 h/night on ? 70% nights in their first month. The overall 2-year mortality rate was 9.4% and CSA secondary to cardiac cause was a significant risk factor for mortality (hazard ratio 1.81, 95% CI 1.09-3.01, <i>P</i> = .02). Comparing pre-ASV and post-ASV initiation, there was no change in the rate of hospitalization (0.72 ± 1.63 versus 0.79 ± 1.44, <i>P</i> = .46), EDV (1.19 ± 2.18 versus 1.26 ± 2.08, <i>P</i> = .54), OPV (31.59 ± 112.42 versus 13.60 ± 17.36, <i>P</i> = .22), or number of prescribed medications (6.68 ± 2.0 versus 5.31 ± 5.86, <i>P</i> = .06). No differences in these outcomes emerged after accounting for adherence to ASV, CSA subtype and comorbidities via multiple regression analysis (all <i>P</i> > .05).<h4>Conclusions</h4>Our cohort of patients with CSA was quite ill and the use of ASV was not associated with a change in health care utilization.2019-01-01T00:00:00Z2019 Jan2021-02-21T10:14:39Z2019-07-25T07:12:17ZS-EPMC63295373062184310.5664/jcsm.7584